Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 4, 23 | -0.27 Increased by +6.90% | -0.29 Increased by +23.78% |
| Mar 9, 23 | -0.22 Increased by +18.52% | -0.31 Increased by +93.65% |
| Nov 10, 22 | -0.25 Increased by +7.41% | -0.34 Increased by +77.85% |
| Aug 5, 22 | -0.30 Decreased by -7.14% | -0.31 Increased by +10.41% |
| May 5, 22 | -0.29 Decreased by -16.00% | -0.32 Increased by +29.30% |
| Mar 17, 22 | -0.27 Increased by +10.00% | -0.28 Increased by +12.76% |
| Oct 28, 21 | -0.27 Decreased by -17.39% | -0.26 Decreased by -14.79% |
| Aug 5, 21 | -0.28 Decreased by -12.00% | -0.24 Decreased by -69.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -14.92 M Increased by +12.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -12.11 M Increased by +25.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -14.32 M Increased by +9.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -17.85 M Decreased by -19.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -17.09 M Decreased by -51.40% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -16.17 M Decreased by -43.17% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -15.79 M Decreased by -78.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -14.94 M Decreased by -98.62% | Decreased by N/A% Decreased by N/A% |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.